ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
Status:
Recruiting
Trial end date:
2033-03-31
Target enrollment:
Participant gender:
Summary
To evaluate the outcome of a prednisolone and low dose methotrexate based protocol in Down
syndrome children with ALL (DS-ALL) in an Asia-wide study. The treatment protocol was
modified based upon backbone of Taiwan Pediatric Oncology Group (TPOG)-ALL protocol in which
risk classification will be guided by level of flow minimal residual disease (MRD) instead.
Phase:
Phase 2
Details
Lead Sponsor:
National Hospital Organization Nagoya Medical Center